Actelion nominates Garnier and Bertolini to board; UK's ABPI names industry outside as new CEO
Swiss biotech firm Actelion (SIX: ATLN) which is under pressure from shareholder Elliott Advisors (which owns 6% of the company) to take control of its board largely with the aim of selling the firm (The Pharma Letters passim), today announced the nomination of Jean-Pierre Garnier and Robert Bertolini for election to the company’s board of directors at the 2011 annual general meeting of shareholders, to be held on May 5.
When elected, Dr Garnier, the first chief executive of the then newly-created UK pharma giant GlaxoSmithKline, will become a vice chairman together with Joseph Scodari. As part of its succession planning, it is the intention of the board that Dr Garnier will be appointed chairman following, as previously announced, the conclusion of Robert Cawthorn’s term of office at the 2012 AGM.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze